A phase IIb clinical study of PDS-0101 in combination with other immune-modulating agents in HPV16-positive and HIV-positive subjects with high-grade anal intraepithelial neoplasia (anal pre-cancer)
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs PDS 0101 (Primary)
- Indications Anal intraepithelial neoplasia
- Focus Therapeutic Use
- 19 Sep 2019 According to a PDS Biotechnology Corporation media release, this trial is expected to start in the first quarter of 2020.
- 29 May 2019 According to a PDS Biotechnology Corporation media release, Dr. Jeffrey Schlom, Chief, LTIB, and Dr. James Gulley, Chief, GMB, at NCI will serve as principal investigators for the NCI, while Dr. Frank Bedu-Addo and Dr. Lauren Wood, PDS Chief Medical Officer, will serve as PDS investigators.
- 12 Oct 2018 New trial record